Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 43
Filter
1.
Violence Against Women ; : 10778012241230326, 2024 Feb 23.
Article in English | MEDLINE | ID: mdl-38400515

ABSTRACT

Insufficient evidence guides mental health service development for survivors of violence against women in Sri Lanka. Provider and survivor perspectives on (1) what constitutes mental health, (2) quality of care, and (3) priority areas and stakeholders for intervention were identified through framework analysis of 53 in-depth interviews. Desired care is chiefly psychosocial-not psychological-prioritizing socioeconomic, parenting, and safe environment needs in non-clinical community settings. Our evidence points strongly to the need to strengthen non-mental health community-based providers as "first contacts" and reassessment of health system-centric interventions which neglect preferred community responses and more holistic approaches accounting for women's full circumstances.

2.
BJPsych Int ; 20(1): 2-4, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36812015

ABSTRACT

When compared with other Asian countries, psychiatric education and training in Sri Lanka has made significant developments during the past two decades, such as introducing psychiatry as a separate final year subject in the undergraduate medical curricula. However, further developments in psychiatric training in medical education are needed.

3.
BMC Psychiatry ; 19(1): 194, 2019 06 24.
Article in English | MEDLINE | ID: mdl-31234824

ABSTRACT

BACKGROUND: Safety monitoring of medicines is essential during therapy for bipolar disorder (BD). We determined the extent of safety monitoring performed according to the International Society for Bipolar Disorders (ISBD) guidelines in patients with BD attending the main tertiary care psychiatry clinics in Sri Lanka to give realistic recommendations for safety monitoring in resource limited settings. METHODS: Patients diagnosed with BD on mood stabilizer medications for more than 1 year were recruited. Data were collected retrospectively from clinic and patient held records and compared with the standards of care recommended by ISBD guidelines for safety monitoring of medicines. RESULTS: Out of 256 patients diagnosed with BD, 164 (64.1%) were on lithium. Only 75 (45.7%) had serum lithium measurements done in the past 6 months and 96 (58.5%) had concentrations recorded at least once in the past year. Blood urea or creatinine was measured in the last 6 months only in 30 (18.3%). Serum electrolytes and thyroid-stimulating hormone (TSH) concentrations were measured in the last year only in 34 (20.7%) and 30 (18.3%) respectively. Calcium concentrations were not recorded in any patient. None of the patients on sodium valproate (n = 119) or carbamazepine (n = 6) had blood levels recorded to establish therapeutic concentrations. Atypical antipsychotics were prescribed for 151 (59%), but only 13 (8.6%) had lipid profiles and only 31 (20.5%) had blood glucose concentration measured annually. Comorbidities experienced by patients influenced monitoring more than the medicines used. Patients with diabetes, hypothyroidism and hypercholesterolemia were more likely to get monitored for fasting blood glucose and (p < 0.001), TSH (p < 0.001) and lipid profiles (p < 0.001). Lithium therapy was associated with TSH monitoring (p < 0.05). Therapy with atypical antipsychotics was not associated with fasting blood glucose or lipid profile monitoring (p > 0.05). A limitation of the study is that although some tests were performed, the results may not have been recorded. CONCLUSIONS: Safety monitoring in BD was suboptimal compared to the ISBD guidelines. ISBD standards are difficult to achieve in resource limited settings due to a multitude of reasons. Realistic monitoring benchmarks and recommendations are proposed for methods to improve monitoring in resource limited settings based on our experience.


Subject(s)
Antipsychotic Agents/blood , Bipolar Disorder/blood , Bipolar Disorder/drug therapy , Drug Monitoring/methods , Health Resources , Tertiary Healthcare/methods , Adolescent , Adult , Aged , Antipsychotic Agents/economics , Antipsychotic Agents/therapeutic use , Bipolar Disorder/economics , Bipolar Disorder/epidemiology , Drug Monitoring/economics , Female , Follow-Up Studies , Health Resources/economics , Humans , Lithium/blood , Lithium/economics , Lithium/therapeutic use , Male , Middle Aged , Retrospective Studies , Sri Lanka/epidemiology , Tertiary Healthcare/economics , Treatment Outcome , Young Adult
4.
Neuropsychiatr Dis Treat ; 13: 2231-2241, 2017.
Article in English | MEDLINE | ID: mdl-28883731

ABSTRACT

Antipsychotic-induced weight gain is a major management problem for clinicians. It has been shown that weight gain and obesity lead to increased cardiovascular and cerebrovascular morbidity and mortality, reduced quality of life and poor drug compliance. This narrative review discusses the propensity of various antipsychotics to cause weight gain, the pharmacologic and nonpharmacologic interventions available to counteract this effect and its impact on adherence. Most antipsychotics cause weight gain. The risk appears to be highest with olanzapine and clozapine. Weight increases rapidly in the initial period after starting antipsychotics. Patients continue to gain weight in the long term. Children appear to be particularly vulnerable to antipsychotic-induced weight gain. Tailoring antipsychotics according to the needs of the individual and close monitoring of weight and other metabolic parameters are the best preventive strategies at the outset. Switching to an agent with lesser tendency to cause weight gain is an option, but carries the risk of relapse of the illness. Nonpharmacologic interventions of dietary counseling, exercise programs and cognitive and behavioral strategies appear to be equally effective in individual and group therapy formats. Both nonpharmacologic prevention and intervention strategies have shown modest effects on weight. Multiple compounds have been investigated as add-on medications to cause weight loss. Metformin has the best evidence in this respect. Burden of side effects needs to be considered when prescribing weight loss medications. There is no strong evidence to recommend routine prescription of add-on medication for weight reduction. Heterogeneity of study methodologies and other confounders such as lifestyle, genetic and illness factors make interpretation of data difficult.

5.
Ceylon Med J ; 62(4): 207-209, 2017 12 26.
Article in English | MEDLINE | ID: mdl-29390595

Subject(s)
Humanities , Medicine , Humans
6.
Ceylon Med J ; 62(4): 222-27, 2017 12 26.
Article in English | MEDLINE | ID: mdl-29390598

ABSTRACT

Background: Mental illness contributes significantly to the global disease burden. There is great diversity in the manner in which mentally ill patients seek help as this is influenced by their beliefs and the opinion of the family-social support unit. The stigma associated with mental illness is a barrier to effective therapy in Sri Lanka where systematic public awareness programmes are minimal. Objective: To study the help-seeking behaviour and its impact on patients attending a psychiatry clinic of the National Hospital of Sri Lanka. Methods: A cross sectional study was carried out among 120 attendees of the psychiatry clinic of the National Hospital of Sri Lanka. Sample was selected using systematic sampling. Data was collected using an interviewer administered questionnaire. Results: More than half the participants sought psychiatric care as their first help-seeking behaviour and found it significantly more useful than non-psychiatric care alternatives. The average time to seek psychiatric care, irrespective of the pathway to care, was less than one month. The recommendation of the family and the social support unit and perceiving that the symptoms were due to a mental illness were the key factors in determining help-seeking behaviour. The average expense on alternative care was zero. There was no significant difference on the impact to employment among those that chose psychiatry care initially from those that did not. Conclusions: Our findings suggest that mentally ill patients presenting to a tertiary care hospital in Colombo, are likely to seek psychiatric care early. This is probably due to better recognition and knowledge regarding available treatment.


Subject(s)
Health Knowledge, Attitudes, Practice , Mental Disorders/therapy , Patient Acceptance of Health Care/psychology , Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Psychiatry , Social Support , Sri Lanka , Tertiary Care Centers , Time Factors , Young Adult
7.
BMC Psychiatry ; 16(1): 341, 2016 Oct 03.
Article in English | MEDLINE | ID: mdl-27716110

ABSTRACT

BACKGROUND: Most antipsychotics are associated with weight gain and other metabolic complications. Several randomized trials have shown metformin to be effective, but this still hasn't been included in clinical guidelines on managing antipsychotic induced weight gain. METHODS: All double blind placebo controlled trials assessing the efficacy of metformin in the treatment of antipsychotic induced weight gain were included. Cochrane Central Register of Controlled Trials (CENTRAL) and MEDLINE were searched for the period January 2000-December 2015. Meta-analysis was carried out using the random effects model. RESULTS: Meta analysis of 12 published studies with a total of 743 patients found that in patients treated with antipsychotics, metformin treatment resulted in significantly better anthropometric and metabolic parameters than placebo. The mean change in weight was -3.27 kg (95 % CI -4.66 to -1.89) (Z = 4.64, p < 0.001). Metformin compared to placebo resulted in significant reduction in BMI [-1.13 kg/m2 (95 % CI -1.61 to -0.66)] and insulin resistance index [-1.49 (95 % CI -2.40 to -0.59)] but not fasting blood sugar [-2.48 mg/dl (95 % CI -5.54 to 0.57]. CONCLUSION: This meta-analysis confirms that metformin is effective in treating antipsychotic induced weight gain in patients with schizophrenia or schizoaffective disorder.


Subject(s)
Antipsychotic Agents/adverse effects , Metformin/therapeutic use , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , Weight Gain/drug effects , Antipsychotic Agents/therapeutic use , Double-Blind Method , Humans
8.
Ceylon Med J ; 61(3): 118-122, 2016.
Article in English | MEDLINE | ID: mdl-27727411

ABSTRACT

INTRODUCTION: Lifetime prevalence of depression varies across countries and different populations. Depression is a common comorbidity of physical illness. Patients with depression are known to present with somatic symptoms. Depression is under-diagnosed in primary care settings. Objectives To estimate the prevalence of depression in patients attending the outpatient department (OPD) of a tertiary care hospital in the Western Province of Sri Lanka. METHODS: A cross-sectional descriptive study was conducted in the OPD of the National Hospital of Sri Lanka (NHSL). Sample size was 205. Every fifth patient aged between 18 and 60 years who attended the OPD was recruited until the required number was met. Centre for Epidemiologic Studies Depression Scale (CES-D) was used to identify depression. RESULTS: There were 114 (55.6%) females. Mean age was 50 years (SD 13.68).Overall prevalence of depression in the sample was 22.4% (95% CI 16.68-28.20). Prevalence of depression was higher among females 25.4% (95% CI 17.32-33.56) than in males 18.7% (95% CI 10.52- 26.84). Prevalence of severe depression was 15.1% (95% CI 10.18-20.07). Adjusted odds ratios showed that pain related presenting complaints were significantly associated with depression [adjusted OR 1.99 (95% CI 1.01-3.96)]. CONCLUSIONS: Prevalence of depression in outpatients is similar to that reported in other parts of the world. None of the patients with depression presented seeking help for depressive symptoms.


Subject(s)
Depression , Diagnostic Errors/prevention & control , Outpatients/psychology , Adult , Comorbidity , Cross-Sectional Studies , Depression/diagnosis , Depression/epidemiology , Female , Humans , Male , Middle Aged , Outpatient Clinics, Hospital/statistics & numerical data , Prevalence , Psychiatric Status Rating Scales , Severity of Illness Index , Sri Lanka/epidemiology
9.
J Med Case Rep ; 10: 83, 2016 Apr 05.
Article in English | MEDLINE | ID: mdl-27048383

ABSTRACT

BACKGROUND: Simvastatin is commonly prescribed for hypercholesterolemia to reduce vascular risk in patients. Some of these patients have dementia with cognitive defects of several domains. Although protective effects seem to be present, there is emerging evidence that statins cause cognitive impairment. The role of cholesterol in cognitive function is complex. This is reflected in the effects that statins show on cognition functions. The reduction in cholesterol levels seen with statins is effective in improving learning and memory in some patients. However, there is emerging evidence that statins may worsen cognitive function. Similarly, there are major concerns over whether statins alleviate or worsen cognitive problems. The correlation between cholesterol levels and cognitive function is still controversial, mainly due to a lack of robust evidence. CASE PRESENTATION: We report the cases of two Asian patients who developed cognitive deficits after starting simvastatin. A 32-year-old man and a 54-year-old woman developed different but clear cognitive deficits that reversed after stopping simvastatin. CONCLUSIONS: The possibility of new-onset cognitive dysfunction and the deterioration of existing cognitive deficits should be considered when prescribing simvastatin to patients.


Subject(s)
Cognitive Dysfunction/chemically induced , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Simvastatin/adverse effects , Adult , Female , Humans , Hypercholesterolemia/drug therapy , Male , Memory Disorders/chemically induced , Middle Aged
10.
BMC Psychiatry ; 16: 100, 2016 Apr 12.
Article in English | MEDLINE | ID: mdl-27071969

ABSTRACT

BACKGROUND: Abortion is associated with moderate to high risk of psychological problems such as depression, use of alcohol or marijuana, anxiety, depression and suicidal behaviours. The increased risk of depression after spontaneous abortion in Asian populations has not been clearly established. Only a few studies have explored the relationship between grief and depression after abortion. METHODS: A study was conducted to assess the prevalence and risk factors of depressive disorder and complicated grief among women 6-10 weeks after spontaneous abortion and compare the risk of depression with pregnant women attending an antenatal clinic. Spontaneous abortion group consisted of women diagnosed with spontaneous abortion by a Consultant Obstetrician. Women with confirmed or suspected induced abortion were excluded. The comparison group consisted of randomly selected pregnant, females attending the antenatal clinics of the two hospitals. Diagnosis of depressive disorder was made according to ICD-10 clinical criteria based on a structured clinical interview. This assessment was conducted in both groups. The severity of depressive symptoms were assessed using the Patients Health Questionnaire (PHQ-9). Grief was assessed using the Perinatal Grief Scale which was administered to the women who had experienced spontaneous abortion. RESULTS: The sample consisted of 137 women in each group. The spontaneous abortion group (mean age 30.39 years (SD = 6.38) were significantly older than the comparison group (mean age 28.79 years (SD = 6.26)). There were more females with ≥10 years of education in the spontaneous abortion group (n = 54; SD = 39.4) compared to the comparison group (n = 37; SD = 27.0). The prevalence of depression in the spontaneous abortion group was 18.6 % (95 CI, 11.51-25.77). The prevalence of depression in the comparison group was 9.5 % (95 CI, 4.52-14.46). Of the 64 women fulfilling criteria for grief, 17 (26.6 %) also fulfilled criteria for a depressive episode. The relative risk of developing a depressive episode after spontaneous abortion was significantly higher than in females with a viable pregnancy (RR = 2.19, 95 % CI, 1.05 to 4.56). After adjustment for age and period of amenorrhoea, the difference was not significant. Prevalence of complicated grief was 54.74 % (95 % CI, 46.3-63.18). CONCLUSION: The relative risk of developing a depressive episode after spontaneous abortion was not significantly higher compared to pregnant women after taking into account age and period of amenorrhoea (POA). Almost half the women developed complicated grief after spontaneous abortion. Of these, a significant proportion also had features of depressive disorder.


Subject(s)
Abortion, Spontaneous/epidemiology , Abortion, Spontaneous/psychology , Depressive Disorder/epidemiology , Depressive Disorder/psychology , Grief , Adult , Depressive Disorder/diagnosis , Female , Humans , Pregnancy , Risk Factors , Sri Lanka/epidemiology
11.
BMC Res Notes ; 9: 174, 2016 Mar 17.
Article in English | MEDLINE | ID: mdl-26987474

ABSTRACT

BACKGROUND: Prevalence of cannabis use among military populations vary. There is evidence that drug use is associated with combat exposure and PTSD. The objective of the study was to assess the prevalence of cannabis use among Sri Lanka Navy (SLN) personnel and to identify any relationship with cannabis use and combat exposure. METHODS: This cross sectional study was carried out among representative samples of SLN Special Forces (Special Boat Squadron) and regular forces deployed in combat areas. Both Special Forces and regular forces were selected using simple random sampling. Personnel who had served continuously in combat areas during the 1 year period prior to end of combat operations were included in the study. Cannabis use was defined as smoking cannabis at least once during the past 12 months. RESULTS: The sample consisted of 259 Special Forces and 412 regular navy personnel. Prevalence of cannabis use was 5.22% (95% CI 3.53-6.9). There was no significant difference in prevalence of cannabis use among Special Forces personnel compared to regular forces. Cannabis use was significantly higher in the age group 18-24 years [OR 4.42 (95% CI 2.18-8.97)], personnel who were never married [OR 2.02 (95% CI 0.99-4.12)], or had an educational level less than GCE O'Level [OR 4.02 (95% CI 1.17-13.78)]. There was significant association between cannabis use and hazardous alcohol use [adjusted OR 5.47 (95% CI 2.65-11.28)], PTSD [adjusted OR 4.20 (95% CI 1.08-16.38)], GHQ caseness [adjusted OR 2.83 (95% CI 1.18-6.79)] and multiple somatic complaints [adjusted OR 3.61 (95% CI 1.5-8.7)]. Cannabis use was not associated with smoking. Risk of cannabis use was less in those who had seen dead or wounded [adjusted OR 0.42 (95% CI 0.20-0.85)]. Experiencing hostility from civilians was the only combat exposure that significantly increased the risk of cannabis use [adjusted OR 4.06 (95% CI 1.06-15.56)]. CONCLUSIONS: Among Sri Lanka Navy personnel exposed to combat cannabis use was significantly associated with hazardous alcohol use but not smoking. PTSD and other adverse mental health outcomes were associated with an increased risk of cannabis use. Exposure to combat was not associated with increased risk of cannabis use.


Subject(s)
Cannabis/adverse effects , Military Personnel , Substance-Related Disorders/epidemiology , Adult , Combat Disorders/epidemiology , Cross-Sectional Studies , Demography , Humans , Mental Health , Prevalence , Sri Lanka/epidemiology , Wounds and Injuries/epidemiology
12.
Ceylon Med J ; 61(4): 167-170, 2016 12 30.
Article in English | MEDLINE | ID: mdl-28076946

ABSTRACT

Introduction: Only the Mini mental state examination (MMSE) and Montreal Cognitive Assessment scale have been validated in a Sri Lankan population for the assessment of cognitive functions. Both tests are deficient in the number of domains assessed. Therefore validation of Repeatable Battery for Assessment of Neuropsychological Status is important as it assesses most of the cognitive domains. Objectives: To culturally adapt RBANS and investigate the validity and reliability of culturally adapted RBANS (RBANS-S). Methods: Fifty four participants with major neurocognitive disorder and 60 normal controls aged >50 were administered with RBANS-S at the Cognitive Assessment Unit, Faculty of Medicine, Colombo and National Hospital of Sri Lanka. The participants were selected after a detailed clinical assessment according to Diagnostic and Statistical Manual ­ 5 criteria. Data were analysed using SPSS data package. Results: The mean age of the sample was 69.5 years. RBANS-S total scale correlated highly with MMSE total score, (Pearson correlational coefficient = 0.793 p=0.01). Criterion validity was assessed using receiver operating curve characteristic analysis and the area under the curve was 0.937. RBANS-S showed strong concurrent validity us indicated by its significant correlations with the MMSE. All of the RBANS-S subtests demonstrated significant correlations with the MMSE subsets. The sensitivity and specificity for RBANS-S was 89% and 85% respectively at a totals score of 80.5. The RBANS-S yielded a reliability coefficient of 0.929. Conclusions: Culturally adapted RBANS-S is a valid and reliable instrument which can be used in assessment of cognitive functions.

13.
J Geriatr Psychiatry Neurol ; 29(3): 115-9, 2016 May.
Article in English | MEDLINE | ID: mdl-26392481

ABSTRACT

BACKGROUND: The Montgomery-Asberg Depression Rating Scale (MADRS) is commonly used to assess major depression in Parkinson disease (PD), but studies on its utility are few. This study examines the validity and factor structure of MADRS in population with PD. METHODS: In 104 patients with idiopathic PD, major depression was diagnosed by Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision; DSM-IV-TR) criteria, and all patients were rated by MADRS. RESULTS: The MADRS showed good concurrent validity with DSM-IV-TR criteria. The diagnostic cutoff was established as 16/17 (sensitivity 97.43, specificity 100%, positive predictive value 100%, and negative predictive value 98.48%). Factor analysis identified 3 factors, accounting for 76% of total variance: "sadness-anhedonia" comprising apparent sadness, reported sadness, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal ideas; "anxiety" with reduced sleep and inner tension; and "vegetative symptoms" with reduced appetite. CONCLUSION: The MADRS has diagnostic utility in major depression in PD. The 3-factor structure of MADRS may help to understand the different dimensions of major depression and identify distinct symptom subgroups in this population.


Subject(s)
Depression/complications , Depression/diagnosis , Depressive Disorder, Major/complications , Depressive Disorder, Major/diagnosis , Factor Analysis, Statistical , Parkinson Disease/complications , Psychiatric Status Rating Scales/standards , Adult , Aged , Aged, 80 and over , Anhedonia , Anxiety/complications , Anxiety/diagnosis , Anxiety Disorders , Depression/classification , Depressive Disorder, Major/classification , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
14.
J Psychopharmacol ; 29(12): 1255-61, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26510448

ABSTRACT

BACKGROUND: Antipsychotic-induced weight gain causes serious health problems. We investigated the efficacy and safety of metformin in treating antipsychotic-induced weight gain in South Asian patients. METHODS: Sixty six adult patients with schizophrenia or schizoaffective disorder treated, with atypical antipsychotics, and who had increased by more than 10% their pre treatment body weight, were randomly assigned to receive metformin or placebo in a double-blind study. Patients received usual treatment and metformin 500 mg or placebo twice daily for 24 weeks. The primary outcome measure was change in body weight from baseline to week 24. Linear mixed models were used in the analysis. RESULTS: Mean change in body weight in the metformin group was -1.56 kg (95% CI=-3.06 to -0.05) and 1.0 kg (95% CI=0.03-1.97) in the placebo group. Between-group difference was 2.56 kg. At 24 weeks the between-group difference showed significant time-by-treatment interaction (F=3.23, p=0.004). Between-group difference in BMI showed significant time-by-treatment interaction (F=3.41 p=0.03). There was no significant difference in waist-hip ratio or fasting blood sugar. CONCLUSIONS: Metformin is effective in reducing weight in South Asian patients with schizophrenia or schizoaffective disorder who had increased their body by more than 10% after treatment with atypical antipsychotics.


Subject(s)
Antipsychotic Agents/adverse effects , Metformin/therapeutic use , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , Weight Gain/drug effects , Adult , Blood Glucose/drug effects , Body Mass Index , Body Weight/drug effects , Double-Blind Method , Female , Humans , Hypoglycemic Agents/therapeutic use , Insulin Resistance/physiology , Male , Obesity/drug therapy
15.
BMC Psychiatry ; 14: 278, 2014 Sep 30.
Article in English | MEDLINE | ID: mdl-25266218

ABSTRACT

BACKGROUND: Depression is common in Parkinson's disease (PD), and has a significant impact on the functional level of those affected. It is well studied in Western populations but data from Asia is limited. This study aims to estimate the prevalence of depression among PD patients attending a tertiary care outpatient clinic in Sri Lanka and identify potential risk factors. METHODS: One hundred and four consecutive idiopathic PD patients as defined by the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria were recruited to the study. An interviewer administered questionnaire, the Hoehn-Yahr staging scale and the Schwab-England Activities of Daily Living Scale (SEADL) were used for assessment. Depression was diagnosed through a semi-structured clinical interview based on DSM-IV-TR criteria and all subjects were rated with the Montgomery-Asberg Depression Rating Scale (MADRS). RESULTS: The prevalence of depression in the study population was 37.5%. Among the depressed 12 (30.8%) had mild depression, 21 (53.8%) moderate depression and 6 (15.4%) had severe depression. Depression was significantly associated with the stage of PD, functional impairment, civil status, educational level, caregiver dependence and concomitant diabetes mellitus. CONCLUSION: A significant proportion of PD patients suffers from depression. The prevalence rate of depression in the sample was similar to that reported in previous studies. Depression in PD is significantly associated with functional impairment.


Subject(s)
Depressive Disorder, Major/epidemiology , Parkinson Disease/epidemiology , Activities of Daily Living , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Depressive Disorder, Major/etiology , Female , Humans , Male , Middle Aged , Parkinson Disease/psychology , Prevalence , Psychiatric Status Rating Scales , Risk Factors , Sri Lanka/epidemiology
16.
PLoS One ; 9(9): e108113, 2014.
Article in English | MEDLINE | ID: mdl-25254557

ABSTRACT

The main aim of this study was to assess the mental health status of the Navy Special Forces and regular forces three and a half years after the end of combat operations in mid 2009, and compare it with the findings in 2009. This cross sectional study was carried out in the Sri Lanka Navy (SLN), three and a half years after the end of combat operations. Representative samples of SLN Special Forces and regular forces deployed in combat areas were selected using simple random sampling. Only personnel who had served continuously in combat areas during the one year period prior to the end of combat operations were included in the study. The sample consisted of 220 Special Forces and 275 regular forces personnel. Compared to regular forces a significantly higher number of Special Forces personnel had experienced potentially traumatic events. Compared to the period immediately after end of combat operations, in the Special Forces, prevalence of psychological distress and fatigue showed a marginal increase while hazardous drinking and multiple physical symptoms showed a marginal decrease. In the regular forces, the prevalence of psychological distress, fatigue and multiple somatic symptoms declined and prevalence of hazardous drinking increased from 16.5% to 25.7%. During the same period prevalence of smoking doubled in both Special Forces and regular forces. Prevalence of PTSD reduced from 1.9% in Special Forces to 0.9% and in the regular forces from 2.07% to 1.1%. Three and a half years after the end of combat operations mental health problems have declined among SLN regular forces while there was no significant change among Special Forces. Hazardous drinking among regular forces and smoking among both Special Forces and regular forces have increased.


Subject(s)
Health Status , Mental Health , Military Personnel/psychology , Adult , Cross-Sectional Studies , Follow-Up Studies , Humans , Male , Middle Aged , Prevalence , Risk Factors , Sri Lanka , Stress Disorders, Post-Traumatic/epidemiology , Young Adult
17.
BMC Res Notes ; 7: 635, 2014 Sep 12.
Article in English | MEDLINE | ID: mdl-25214394

ABSTRACT

BACKGROUND: The literature describing the long-term use of lithium carbonate to reinstate reduced levels of white blood cell counts in patients treated with clozapine is scarce. We describe a case of successful recommencement of clozapine on a patient who developed risk level of neutropenia which was corrected by lithium carbonate. He was followed up for a period of one year. CASE PRESENTATION: We report a 40-year-old Sri Lankan male who developed neutropenia and low white blood cell counts following commencement of clozapine. We were successful in restarting clozapine after the addition of lithium carbonate to increase the cell counts. Clozapine was increased to 700 mg a day with 500 mg of lithium carbonate. The patient remains stable after one year with no further episodes of neutropenia. CONCLUSION: Lithium carbonate can successfully be used to treat clozapine-induced neutropenia.


Subject(s)
Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Lithium Compounds/therapeutic use , Neutropenia/drug therapy , Adult , Antipsychotic Agents/therapeutic use , Clozapine/therapeutic use , Humans , Male , Neutropenia/chemically induced , Schizophrenia/drug therapy
18.
BMC Res Notes ; 7: 574, 2014 Aug 27.
Article in English | MEDLINE | ID: mdl-25164031

ABSTRACT

BACKGROUND: Phagophobia is a rare disorder and the literature is sparse. There is no specific treatment described for this life threatening condition. CASE PRESENTATION: The patient is a 25-year-old Sri Lankan female with recurrent difficulty in swallowing. Following her initial episode which lasted one year, she presented to us with inability to swallow for one week. She was dependent on liquids and semisolids. The medical team confidently excluded an organic cause. She had difficulty swallowing solids with behaviours like swallowing with the aid of water and swallowing small boluses. She had difficulty eating in front of a crowd as well. She was preoccupied with misconceptions related to food and gastrointestinal disorders like gastritis. The symptom was soon becoming a maladaptive coping mechanism as it occurred when she was under stress and had difficulty solving a problem. The patient was managed with graded exposure and cognitive techniques. CONCLUSION: The possibility of a psychological cause for dysphagia should be borne in mind although the occurrence is rare. Although no definitive treatment methods for phagophobia are described, cognitive behavioural techniques can successfully be used in the treatment.


Subject(s)
Deglutition , Phobic Disorders/diagnosis , Adaptation, Psychological , Adult , Female , Humans , Phobic Disorders/psychology
19.
Ceylon Med J ; 59(2): 39-44, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24977420

ABSTRACT

OBJECTIVES: The objective was to study the prevalence of fatigue symptoms among Special Forces and regular forces military personnel deployed in combat areas and to explore factors associated with fatigue symptoms. METHODS: This is a cross sectional study of representative samples of Sri Lanka Navy Special Forces and regular forces deployed in combat areas continuously for at least one year. Fatigue was measured using a 12 item fatigue scale. Symptoms of common mental disorder were identified using the General Health questionnaire 12 (GHQ-12). Multiple physical symptoms were elicited using a checklist of symptoms. PTSD was diagnosed using the 17-item National Centre for PTSD checklist civilian version (PCL-C). RESULTS: Sample consisted of 259 Special Forces and 412 regular navy personnel. Prevalence of fatigue over the last month was 13.41% (95% CI 10.83-16.00). Prevalence was significantly less in the Special Forces (5.4%) than in the regular forces (18.4%) [OR 0.38 (95% CI 0.17-0.82)]. Only two types of combat exposure "thought I might be killed" and "coming under mortar, missile and artillery fire" were significantly associated with fatigue symptoms. Fatigue was strongly associated with symptoms of common mental illness [adjusted OR 12.82 (95% CI 7.10-23.12)], PTSD [adjusted OR 9.08 (95% CI 2.84-29.0)] and multiple somatic symptoms [adjusted OR 9.85 (95% CI 5.42-17.9)]. Fatigue was significantly associated with functional impairment. CONCLUSIONS: Prevalence of fatigue was significantly lower in the Special Forces despite high combat exposure. Fatigue was associated only with indicators of intense combat exposure. Fatigue caused significant functional impairment even after adjusting for psychological morbidity.


Subject(s)
Fatigue/epidemiology , Fatigue/psychology , Military Personnel/psychology , Stress Disorders, Post-Traumatic/epidemiology , Adult , Cross-Sectional Studies , Humans , Male , Naval Medicine , Prevalence , Sri Lanka , Warfare , Young Adult
20.
Depress Res Treat ; 2014: 768978, 2014.
Article in English | MEDLINE | ID: mdl-24795822

ABSTRACT

The Patient Health Questionnaire (PHQ-9) was adapted and translated into Sinhala. Sample consisted of 75 participants diagnosed with MDD according to DSM-IV criteria and 75 gender matched controls. Concurrent validity was assessed by correlating total score of PHQ-9 with that of Centre for Epidemiological Studies Depression Scale (CESD). The Structured Clinical Interview for DSM-IV (SCID-II) conducted by a psychiatrist was the gold standard. Mean age of the sample was 33.0 years. There were 91 females (60.7%). There was significant difference in the mean PHQ-9 scores between cases (14.71) and controls (2.55) (P < 0.001). The specificity of the categorical algorithm was 0.97; the sensitivity was 0.58. Receiver operating characteristic (ROC) analysis found that cut-off score of ≥10 had sensitivity of 0.75 and specificity of 0.97. The area under the curve (AOC) was 0.93. The sensitivity of the two-item screener (PHQ-2) was 0.80 and the specificity was 0.97. Cronbach's alpha was 0.90. The PHQ-9 is a valid and reliable instrument for diagnosing MDD in a non-Western population. The threshold algorithm is recommended for screening rather than the categorical algorithm. The PHQ-2 screener has good sensitivity and specificity and is recommended as a quick screening instrument.

SELECTION OF CITATIONS
SEARCH DETAIL
...